News >

FDA Grants Novel Triplet Breakthrough Designation in BRAF+ mCRC

Jason M. Broderick @jasoncology
Published: Tuesday, Aug 07, 2018

Dr Victor Sandor

Victor Sandor, MD

The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor encorafenib (Braftovi), the MEK inhibitor binimetinib (Mektovi), and the EGFR inhibitor cetuximab (Erbitux) for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC) following 1 or 2 prior lines of treatment in the metastatic setting.

mutant unresectable or metastatic melanoma, as detected by an FDA-approved test.
Array Biopharma Receives FDA Breakthrough Therapy Designation for Braftovi™ in Combination With Mektovi® and Cetuximab For BRAFV600E-Mutant Metastatic Colorectal Cancer. Array BioPharma Inc. Posted August 7, 2018. Accessed August 7, 2018. https://bit.ly/2vJUhEA.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x